Survival after introduction of adjuvant treatment in stage III melanoma: a nationwide registry-based study.
Journal
Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089
Informations de publication
Date de publication:
07 09 2023
07 09 2023
Historique:
accepted:
10
05
2023
received:
18
02
2023
revised:
25
04
2023
medline:
8
9
2023
pubmed:
25
5
2023
entrez:
25
5
2023
Statut:
ppublish
Résumé
Adjuvant treatments with PD-1 and BRAF+MEK inhibitors statistically significantly prolong recurrence-free survival in stage III cutaneous melanoma. Yet, the effect on overall survival is still unclear. Based on recurrence-free survival outcomes, these treatments have been approved and widely implemented. The treatments have considerable side effects and costs, and overall survival effect remains a highly anticipated outcome. Clinical and histopathological parameters were obtained from the Swedish Melanoma Registry for patients diagnosed with stage III melanoma between 2016 and 2020. The patients were divided depending on if they were diagnosed before or from July 2018, based on the timepoint when adjuvant treatment was introduced in Sweden. Patients were followed up until the end of 2021. In this cohort study, melanoma-specific and overall survival were calculated using the Kaplan-Meier method and Cox-regression analyses. There were 1371 patients diagnosed with stage III primary melanoma in Sweden in 2016-2020. The 2-year overall survival rates, comparing the 634 patients in the precohort and the 737 in the postcohort, were 84.3% (95% confidence interval [CI] = 81.4% to 87.3%) and 86.1% (95% CI = 83.4% to 89.0%), respectively, with an adjusted hazard ratio of 0.91 (95% CI = 0.70 to 1.19, P = .51). Further, no statistically significant overall or melanoma-specific survival differences were seen when comparing the precohort and the postcohort in different subgroups for age, sex, or tumor characteristics. In this nationwide population-based and registry-based study, no survival benefit was detected in patients diagnosed before or after the implementation of adjuvant treatment in stage III melanoma. These findings encourage a careful assessment of the current recommendations on adjuvant treatment.
Sections du résumé
BACKGROUND
Adjuvant treatments with PD-1 and BRAF+MEK inhibitors statistically significantly prolong recurrence-free survival in stage III cutaneous melanoma. Yet, the effect on overall survival is still unclear. Based on recurrence-free survival outcomes, these treatments have been approved and widely implemented. The treatments have considerable side effects and costs, and overall survival effect remains a highly anticipated outcome.
METHODS
Clinical and histopathological parameters were obtained from the Swedish Melanoma Registry for patients diagnosed with stage III melanoma between 2016 and 2020. The patients were divided depending on if they were diagnosed before or from July 2018, based on the timepoint when adjuvant treatment was introduced in Sweden. Patients were followed up until the end of 2021. In this cohort study, melanoma-specific and overall survival were calculated using the Kaplan-Meier method and Cox-regression analyses.
RESULTS
There were 1371 patients diagnosed with stage III primary melanoma in Sweden in 2016-2020. The 2-year overall survival rates, comparing the 634 patients in the precohort and the 737 in the postcohort, were 84.3% (95% confidence interval [CI] = 81.4% to 87.3%) and 86.1% (95% CI = 83.4% to 89.0%), respectively, with an adjusted hazard ratio of 0.91 (95% CI = 0.70 to 1.19, P = .51). Further, no statistically significant overall or melanoma-specific survival differences were seen when comparing the precohort and the postcohort in different subgroups for age, sex, or tumor characteristics.
CONCLUSIONS
In this nationwide population-based and registry-based study, no survival benefit was detected in patients diagnosed before or after the implementation of adjuvant treatment in stage III melanoma. These findings encourage a careful assessment of the current recommendations on adjuvant treatment.
Identifiants
pubmed: 37227040
pii: 7179563
doi: 10.1093/jnci/djad081
pmc: PMC10483326
doi:
Substances chimiques
Adjuvants, Immunologic
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1077-1084Informations de copyright
© The Author(s) 2023. Published by Oxford University Press.
Références
Melanoma Res. 2023 Oct 1;33(5):388-397
pubmed: 36988401
Cancer Discov. 2022 Mar 1;12(3):644-653
pubmed: 34764195
Int J Cancer. 2016 Aug 1;139(3):543-53
pubmed: 27004457
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Eur J Cancer. 2019 Sep;119:1-10
pubmed: 31400634
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
N Engl J Med. 2011 Jun 30;364(26):2507-16
pubmed: 21639808
N Engl J Med. 2018 May 10;378(19):1789-1801
pubmed: 29658430
Eur J Epidemiol. 2017 Sep;32(9):765-773
pubmed: 28983736
Lancet Oncol. 2019 Jul;20(7):948-960
pubmed: 31160251
Lancet. 2022 Apr 30;399(10336):1718-1729
pubmed: 35367007
Int J Cancer. 2023 Jul 1;153(1):133-140
pubmed: 36752579
Lancet Oncol. 2021 May;22(5):643-654
pubmed: 33857412
Eur J Cancer. 2016 May;59:171-178
pubmed: 27046697
Lancet Oncol. 2015 May;16(5):522-30
pubmed: 25840693
N Engl J Med. 2017 Nov 9;377(19):1824-1835
pubmed: 28891423
Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-7
pubmed: 35658502
JAMA Netw Open. 2022 Jun 1;5(6):e2216058
pubmed: 35687338
Lancet Oncol. 2019 Jul;20(7):e378-e389
pubmed: 31267972
N Engl J Med. 2017 Nov 9;377(19):1813-1823
pubmed: 28891408
Lancet Oncol. 2020 Nov;21(11):1465-1477
pubmed: 32961119
J Clin Oncol. 2018 Dec 10;36(35):3441-3449
pubmed: 30343620
J Eur Acad Dermatol Venereol. 2023 May;37(5):894-906
pubmed: 36433688
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
N Engl J Med. 2020 Sep 17;383(12):1139-1148
pubmed: 32877599
N Engl J Med. 2015 Jun 25;372(26):2521-32
pubmed: 25891173
Eur J Cancer. 2021 Nov;158:234-245
pubmed: 34600790
J Clin Oncol. 2009 Dec 20;27(36):6199-206
pubmed: 19917835
Lancet. 2012 Jul 28;380(9839):358-65
pubmed: 22735384
N Engl J Med. 2014 Nov 13;371(20):1877-88
pubmed: 25265492
Eur J Cancer. 2022 Mar;163:79-87
pubmed: 35042070